Cardiogeni Plc is a biotechnology company focused on developing cell therapy medicines for the treatment of heart failure. Its lead product, CLXR-001, is designed for administration during coronary artery bypass surgery. The company operates primarily in the Gulf Cooperation Council (GCC) region, where it is advancing clinical development and commercialization efforts through a joint venture established in the United Arab Emirates. Cardiogeni generates revenue through licensing agreements and aims to secure funding for clinical trials and product development.
No recent RNS announcements for Cardiogeni Plc across CGNI.
No recent RNS announcements for Cardiogeni Plc across CGNI.